↓ Skip to main content

Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial

Overview of attention for article published in Trials, October 2013
Altmetric Badge

Mentioned by

blogs
1 blog
twitter
11 X users
peer_reviews
1 peer review site

Citations

dimensions_citation
87 Dimensions

Readers on

mendeley
122 Mendeley
Title
Standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI): study protocol for a randomized controlled trial
Published in
Trials, October 2013
DOI 10.1186/1745-6215-14-320
Pubmed ID
Authors

Orla M Smith, Ron Wald, Neill KJ Adhikari, Karen Pope, Matthew A Weir, Sean M Bagshaw

Abstract

Acute kidney injury is a common and devastating complication of critical illness, for which renal replacement therapy is frequently needed to manage severe cases. While a recent systematic review suggested that "earlier" initiation of renal replacement therapy improves survival, completed trials are limited due to small size, single-centre status, and use of variable definitions to define "early" renal replacement therapy initiation.

X Demographics

X Demographics

The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Denmark 1 <1%
Unknown 121 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 18 15%
Student > Postgraduate 15 12%
Student > Master 13 11%
Student > Ph. D. Student 11 9%
Student > Doctoral Student 11 9%
Other 25 20%
Unknown 29 24%
Readers by discipline Count As %
Medicine and Dentistry 67 55%
Nursing and Health Professions 5 4%
Biochemistry, Genetics and Molecular Biology 3 2%
Pharmacology, Toxicology and Pharmaceutical Science 3 2%
Engineering 3 2%
Other 8 7%
Unknown 33 27%